BIOSIMILAR CONTRACT MANUFACTURING MARKET Size and trends

Biosimilar Contract Manufacturing Market Size and Trends

The Global Biosimilar Contract Manufacturing Market is estimated to be valued at USD 12.42 Bn in 2025 and is expected to reach USD 35.35 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.1% from 2025 to 2032.

Key Takeaways of the Biosimilar Contract Manufacturing Market:

• The recombinant non-glycosylated proteins segment is expected to contribute the highest share of the market with a share of 52.6% in 2025.
• The oncology segment is expected to contribute the highest share of the market with 31.6% in 2025.
• The mammalian manufacturing segment is expected to contribute the highest share of the market with 58.6% in 2025.
• North America is expected to top the market with 37.7% share, followed by Asia Pacific with 28.2% share in 2025.

Market Overview:

The market growth is attributed to the rising demand for biosimilar drugs due to the increasing prevalence of chronic diseases. In addition, the expiration of patents for biologic drugs and rising demand for affordable healthcare are expected to provide market players with lucrative opportunities. However, high costs associated with biosimilar development and manufacturing may hamper the market growth.